Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025HepatologyOpen Access

Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

FFFriedrich FoersterLWLucas WiesmannPBPaula Bark

Discussion

Loading...

Member takes

Overview

Review highlights immunotherapy's evolution in hepatocellular carcinoma, emphasizing new targets and biomarker usage.

Key Points

  • Immunotherapy has transformed the treatment landscape for hepatocellular carcinoma, boosting survival rates.
  • Established targets like PD-1 and CTLA-4 are pivotal in current therapeutic strategies for HCC.
  • Molecular biomarkers are underutilized despite their potential to enhance treatment precision for patients.
  • Novel immunotherapeutic targets are being explored in clinical trials, indicating a promising future for HCC treatment.

Cite This Study

Foerster et al. (2025) studied this question.

synapsesocial.com/papers/68e02f46f0e39f13e7fa2dbahttps://doi.org/10.1097/hep.0000000000001554
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Contemporary Use of Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma2025
  2. 2Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma2025
  3. 3The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma2026
  4. 4Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances2026
  5. 5Recent advance in immune checkpoint inhibitors-based therapy of advanced hepatocellular carcinoma2024